Abstract
Rare diseases impact the lives of an estimated 350 million people worldwide, and yet about 90% of rare diseases remain without an approved treatment. New technologies have become available, such as gene and oligonucleotide therapies, that offer great promise in treating rare diseases. However, progress toward the development of therapies to treat these diseases is hampered by a limited understanding of the course of each rare disease, how changes in disease progression occur and can be effectively measured over time, and challenges in designing and running clinical trials in diseases where the natural history is poorly characterized. Data that could be used to characterize the natural history of each disease has often been collected in various ways, including in electronic health records, patient-report registries, clinical natural history studies, and in past clinical trials. However, each data source contains a limited number of subjects and different data elements, and data is frequently kept proprietary in the hands of the study sponsor rather than shared widely across the rare disease community. The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) is an FDA-funded effort to overcome these persistent challenges. By aggregating data across all rare diseases and making that data available to the community to support understanding of rare disease natural history and inform drug development, RDCA-DAP aims to accelerate the regulatory approval of new therapies. RDCA-DAP curates, standardizes, and tags data across rare disease datasets to make it findable within the database, and contains a built-in analytics platform to help visualize, interpret, and use it to support drug development. RDCA-DAP will coordinate data and tool resources across non-profit, commercial, and for-profit entities to serve a diverse array of rare disease stakeholders that includes academic researchers, drug developers, FDA reviewers and of course patients and their caregivers. Drug development programs utilizing the RDCA-DAP will be able to leverage existing data to support their efforts and reach definitive decisions on the efficacy of their therapeutics more efficiently and more rapidly than ever.
Similar content being viewed by others
References
Orphan Drug Act, 1983. https://www.govinfo.gov/content/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf
Orphan Drug Act - Relevant Excerpts, US FDA 2013, https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts
Kempf L, Goldsmith JC, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet. 2018;176:773–83.
Contesse MG, Valentine JE, Wall TE, Leffler MG. The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overview. Adv Ther. 2019;36(5):997–1010. https://doi.org/10.1007/s12325-019-00920-x.
Rare Disease Day 2020: FDA Continues Important Work on Treatments for Rare Diseases, https://www.fda.gov/news-events/fda-voices/rare-disease-day-2020-fda-continues-important-work-treatments-rare-diseases#:~:text=The%20FDA%20has%20approved%20drugs,44%25%2C%20were%20orphan%20products.
Boulanger V, Schlemmer M, Rossov S, et al. Establishing patient registries for rare diseases: rationale and challenges. Pharm Med. 2020;34:185–90. https://doi.org/10.1007/s40290-020-00332-1.
Guidance for Industry, Rare Diseases: Natural History Studies for Drug Development, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Office of Orphan Products Development (OOPD), March 2019. https://www.fda.gov/media/122425/download
Burton J, Bhattacharya S, Romero K, Conrado DJ. Open data for clinical pharmacology. Clin Pharmacol Ther. 2020;107(4):703–6.
Wilkinson M, Dumontier M, Aalbersberg I, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3: 160018. https://doi.org/10.1038/sdata.2016.18.
U.S. Food and Drug Administration. Code of Federal Regulations, Title 21, Sec. 314.50: Content and formatof an Application. 2015. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.50. Accessed September 25, 2021
Novel Drug Approvals for 2019, Center for Drug Evaluation and Research (CDER), US FDA, https://www.fda.gov/drugs/newdrugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019, Content current as of: 01/14/2020. Accessed June 4, 2022
Wu, et al. Pharmacoepidemiol Drug Saf. 2020;29:1213–8.
Karpen SR, White JK, Mullin AP, Odoherty I, Hudson LD, Romero K, Sivakumaran S, Stephenson D, Turner EC, Larkindale J. Effective data sharing as a conduit for advancing medical product development. Ther Innov Regul Sci. 2021;55(3):591–600. https://doi.org/10.1007/s43441-020-00255-8.
Conrado DJ, Larkindale J, Berg A, Hill M, Burton J, Abrams KR, Abresch RT, Bronson A, Chapman D, Crowther M, Duong T, Gordish-Dressman H, Harnisch L, Henricson E, Kim S, McDonald CM, Schmidt S, Vong C, Wang X, Wong BL, Yong F, Romero K. Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy. J Pharmacokinet Pharmacodyn. 2019;46(5):441–55. https://doi.org/10.1007/s10928-019-09642-7.
Denton N, Molloy M, Charleston S, et al. Data silos are undermining drug development and failing rare disease patients. Orphanet J Rare Dis. 2021;16:161. https://doi.org/10.1186/s13023-021-01806-4.
Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, Mohs R, Lalonde R, Sinha V, Wang Y, Brown D, Isaac M, Vamvakas S, Hemmings R, Pani L, Bain LJ, Corrigan B. The future is now: model-based clinical trial design for Alzheimer’s disease. Clin Pharmacol Ther. 2015;97(3):210–4.
Romero K, Conrado D, Burton J, Nicholas T, Sinha V, Macha S, Ahamadi M, Cedarbaum J, Seibyl J, Marek K, Basseches P, Hill D, Somer E, Gallagher J, Dexter DT, Roach A, Stephenson D. Molecular neuroimaging of the dopamine transporter as a patient enrichment biomarker for clinical trials for early Parkinson’s disease. Clin Transl Sci. 2019;12(3):240–6.
Shefchek KA, Harris NL, Gargano M, Matentzoglu N, Unni D, Brush M, Keith D, Conlin T, Vasilevsky N, Zhang XA, Balhoff JP, Babb L, Bello SM, Blau H, Bradford Y, Carbon S, Carmody L, Chan LE, Cipriani V, Cuzick A, Della Rocca M, Dunn N, Essaid S, Fey P, Grove C, Gourdine JP, Hamosh A, Harris M, Helbig I, Hoatlin M, Joachimiak M, Jupp S, Lett KB, Lewis SE, McNamara C, Pendlington ZM, Pilgrim C, Putman T, Ravanmehr V, Reese J, Riggs E, Robb S, Roncaglia P, Seager J, Segerdell E, Similuk M, Storm AL, Thaxon C, Thessen A, Jacobsen JOB, McMurry JA, Groza T, Köhler S, Smedley D, Robinson PN, Mungall CJ, Haendel MA, Munoz-Torres MC, Osumi-Sutherland D. The Monarch Initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species. Nucleic Acids Res. 2020;48:704–15. https://doi.org/10.1093/nar/gkz997.
Funding
Funding was provided by U.S. Food and Drug Administration (Grant No. 2U18FD005320).
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Larkindale, J., Betourne, A., Borens, A. et al. Innovations in Therapy Development for Rare Diseases Through the Rare Disease Cures Accelerator-Data and Analytics Platform. Ther Innov Regul Sci 56, 768–776 (2022). https://doi.org/10.1007/s43441-022-00408-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43441-022-00408-x